Tegafur/uracil cost effective for patients with NSCLC
- PDF / 139,543 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 14 Downloads / 163 Views
All patients
T1 disease
T2 disease
Tegafur/ uracil No treatment Tegafur/ uracil No treatment Tegafur/ uracil No treatment
Total costs ($US)
Projected survival (years)
ICER ($US/LYG)
13 141
14.9
4 774
8957
14.0
13 119
15.1
7865
14.8
13 198
14.3
11 814
12.0
17 745
603
However, the use of tegafur/uracil resulted in lower post-relapse treatment costs than no treatment ($US1391 vs $US2375), and terminal care costs ($US1427 vs $US2148). Tegafur/uracil therapy was associated with an ICER of $US4744 per LYG; when T1 and T2 disease was considered, the ICER was $US17 745 and $US603 per LYG, respectively. Sensitivity analysis showed the findings were stable to changes in key parameters. * Costs ($US1 = 113.8 Japanese yen) included those associated with consultations, drug administration, post-relapse treatment, treatment for adverse events, and terminal care. Costs and outcomes were discounted by a rate of 3% annually. Ikeda S, et al. Cost-effectiveness of adjuvant chemotherapy with uracil-tegafur, an oral fluoropyrimidine derivative, in patients with non-small-cell lung cancer in Japan. Value in Health 9: 106 (plus poster) abstr. PCN8, No. 3, May-Jun 801066669 2006
1173-5503/10/0507-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
PharmacoEconomics & Outcomes News 15 Jul 2006 No. 507
1
Data Loading...
